


Tubulin polymerization-IN-12

Cat. No.:	HY-146818
CAS No.:	2377301-45-4
Molecular Formula:	C ₂₃ H ₂₃ N ₅ O ₆
Molecular Weight:	465.46
Target:	Microtubule/Tubulin
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Tubulin polymerization-IN-12 is a tubulin polymerization inhibitor (IC ₅₀ =0.75 μM). Tubulin polymerization-IN-12 arrests cell cycle at G2/M phase, and exhibits cytotoxicity against cancer cells ^[1] .																
In Vitro	<p>Tubulin polymerization-IN-12 (compound 6) shows cytotoxicity against normal human embryonic kidney cells, HEK-293, with an IC₅₀ value of 29.94 μM^[1].</p> <p>Tubulin polymerization-IN-12 (compound 26) inhibits cancer cells with IC₅₀s of 1.02 μM (A549), 0.75 μM (HeLa), 10.91 μM (HCT116), and 29.94 μM (HEK293), respectively^[2].</p> <p>Tubulin polymerization-IN-12 (1 μM, 2 μM, 10 μM; 6 h) inhibits tubulin expression in HeLa cell, and shows 42% inhibition at 10 μM^[2].</p> <p>Tubulin polymerization-IN-12 (0.75 μM-3 μM; 24 h) arrests cell cycle at G2/M phase in HeLa cells^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Immunofluorescence^[2]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HeLa cells</td> </tr> <tr> <td>Concentration:</td> <td>1 μM, 2 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>6 hours</td> </tr> <tr> <td>Result:</td> <td>Dose-dependently decreased the level of α and β tubulin.</td> </tr> </table> <p>Cell Cycle Analysis^[2]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HeLa cells</td> </tr> <tr> <td>Concentration:</td> <td>0.75 μM, 1.5 μM, 3 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Demonstrated 15.03% (0.75 μM), 20.04% (1.50 μM), and 33.47% (3.00 μM) of cell accumulation in G2/M phase.</td> </tr> </table>	Cell Line:	HeLa cells	Concentration:	1 μM, 2 μM	Incubation Time:	6 hours	Result:	Dose-dependently decreased the level of α and β tubulin.	Cell Line:	HeLa cells	Concentration:	0.75 μM, 1.5 μM, 3 μM	Incubation Time:	24 hours	Result:	Demonstrated 15.03% (0.75 μM), 20.04% (1.50 μM), and 33.47% (3.00 μM) of cell accumulation in G2/M phase.
Cell Line:	HeLa cells																
Concentration:	1 μM, 2 μM																
Incubation Time:	6 hours																
Result:	Dose-dependently decreased the level of α and β tubulin.																
Cell Line:	HeLa cells																
Concentration:	0.75 μM, 1.5 μM, 3 μM																
Incubation Time:	24 hours																
Result:	Demonstrated 15.03% (0.75 μM), 20.04% (1.50 μM), and 33.47% (3.00 μM) of cell accumulation in G2/M phase.																

REFERENCES

[1]. Yang F, et al. Synthesis, and biological evaluation of 3, 6-diaryl-[1, 2, 4] triazolo [4, 3-a] pyridine analogues as new potent tubulin polymerization inhibitors[J]. European Journal of Medicinal Chemistry, 2020, 204: 112625.

[2]. Yang F, et al. Novel [1, 2, 4] triazolo [1, 5-a] pyrimidine derivatives as potent antitubulin agents: Design, multicomponent synthesis and antiproliferative activities[J]. Bioorganic Chemistry, 2019, 92: 103260.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA